An Open-Label, Multicenter Study of the Safety and Anti Viral Activity of Brincidofovir (BCV, CMX001) for Ebola Virus Disease

Jazz Pharmaceuticals

Overview

The purpose of this study is to assess the safety and tolerability of Brincidofovir (BCV) when administered as an initial 200mg dose followed by 100mg twice weekly (BIW) for a total of 5 doses.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Conditions

Ebola Virus

Interventions

CMX001DRUG

CMX001 administered as initial dose of 200mg then 100mg BIW for a total of 5 doses.

Eligibility

Sex: ALLMin age: 2 MonthsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Positive for Ebola virus RNA in plasma * Subject must be able to ingest, absorb, and tolerate oral medication * Subject must be willing to use adequate contraception during their participation Exclusion Criteria: \-

Outcomes

Primary Outcomes

Number of Participants with Adverse Events as a Measure of Safety and Tolerability.

Time frame: 4 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.